Actively Recruiting
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Led by Ottawa Hospital Research Institute · Updated on 2026-01-08
662
Participants Needed
12
Research Sites
258 weeks
Total Duration
On this page
Sponsors
O
Ottawa Hospital Research Institute
Lead Sponsor
A
Alberta Cancer Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).
CONDITIONS
Official Title
Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years or older undergoing autologous hematopoietic stem cell transplantation for a hematologic malignancy
- Patients who have provided written informed consent before starting transplantation
You will not qualify if you...
- Previous WHO grade 2, 3, or 4 bleeding event within the past year
- Previous or current unprovoked thrombotic event such as pulmonary embolism, deep vein thrombosis, or cerebral thrombosis
- Current provoked thrombotic event within the last month or still requiring anticoagulant treatment
- Requirement for therapeutic anticoagulant or anti-platelet drugs during transplantation
- Active angina (chest pain of presumed cardiac origin at rest or with activity)
- Current or recent (within 2 weeks) urinary tract bleeding
- Inherited bleeding or clotting disorder
- Coagulopathy with abnormal blood clotting tests beyond defined limits
- History of platelet transfusion refractoriness due to HLA antibodies
- Significant kidney impairment defined by creatinine or eGFR levels
- Pregnant or breastfeeding
- Unwilling or unable to provide informed consent
- Acquired disturbances in color vision (not congenital color blindness)
- Known allergy or sensitivity to Tranexamic Acid or its ingredients
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N4N2
Actively Recruiting
2
Cross Cancer Institute
Edmonton, Alberta, Canada
Actively Recruiting
3
Eastern Regional Health Authority
St. John's, Newfoundland and Labrador, Canada, A1B 3V6
Actively Recruiting
4
Memorial University
St. John's, Newfoundland and Labrador, Canada
Not Yet Recruiting
5
Dalhousie University
Halifax, Nova Scotia, Canada
Not Yet Recruiting
6
Hamilton Health Sciences - Juravinski Hospital and Cancer Centre
Hamilton, Ontario, Canada, L8V 1C3
Actively Recruiting
7
London Health Sciences Centre
London, Ontario, Canada, N6A5W9
Actively Recruiting
8
The Ottawa Hospital
Ottawa, Ontario, Canada, K1H8L6
Actively Recruiting
9
Niagara Health System
St. Catharines, Ontario, Canada, L2S 0A9
Actively Recruiting
10
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Withdrawn
11
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Not Yet Recruiting
12
Saskatchewan Cancer Agency
Saskatoon, Saskatchewan, Canada
Actively Recruiting
Research Team
S
Sohail Robert, RN
CONTACT
A
Alan Tinmouth, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here